shareholdersunite.com

Milestone Scientific has a platform technology for the safe delivery of injections, with one application already commercialized and another one (the CompuFlo) close. The health and cost benefits of the CompuFlo are clear, and there is an obvious and large market with 11 million epidurals per year in the US alone. There has been a […]

[Read more →]

While the company is suffering from the pandemic and the economic fallout, it keeps on investing and can easily afford to do so. This is likely to lead to market share gains as smaller competitors are less well positioned in this environment and can’t keep up or might even go out of business. Hence, the […]

[Read more →]

Duos Technologies has got a foothold in the rail industry where it is automating railcar inspections, and it is adding AI smarts to this process. The basic capabilities of the company can be applied to a whole range of situations and verticals; it is more or less a generic capability. While its rail revenue could […]

[Read more →]

The company has long been struggling to get growing again with a number of false dawns the past decade in a competitive industry. However, it looks like its focus on SaaS solutions is finally starting to pay off, gaining critical mass. The economic effects of the COVID-19 pandemic will hide much of that progress this […]

[Read more →]

The company is making steady progress in terms of market acceptance of its solutions, as well as in terms of financial performance. While there could very well be some headwinds for a couple of quarters due to the pandemic and the economic fallout, we think the company benefits from long-term tailwinds. With the shares really […]

[Read more →]

The company continues to build out its very valuable platform which aligns and simplifies a host of business processes for its customers. Demand for these “re-engineering” capabilities is likely to endure even during the pandemic-induced economic downturn. While the shares are fully valued at the moment, we would be dip buyers, as we’re pretty sure […]

[Read more →]

Synacor is merging with Qumu in an all-stock deal, giving the combination more of a recurring SaaS nature. While the two businesses have been stagnant individually, there are some tentative reasons to think the combination will do better, like a big new customer for Synacor’s ID business. If they do, given the high gross margin […]

[Read more →]

Usio is a payment processor that is close to being adjusted-EBITDA break-even, the only thing that needs to happen is scaling up further. There are legitimate concerns the pandemic could lengthen that path considerably, but the first signs allay some of these fears. The shares are modestly priced, but the company might need more financing. […]

[Read more →]

The company’s shares plunged, as investors worry about cash flow and uncertainty about business conditions. While we share some of these concerns, a business update should at least allay some of these fears, although cash remains perilously low and might very well require action. In the process of writing, there has been a quite massive […]

[Read more →]

The company had a stellar year with 48% revenue growth, margin expansion and a profit explosion. Some worries emerged about the company’s financial control mechanisms and the impact of COVID-19, but the shares have sold off in a very exaggerated manner. The company is financially very sound, the control issues seem to be solved and […]

[Read more →]